Stock Research
|
AZN Drug Gets Positive Ruling In US
AstraZeneca plc (NYSE:AZN) announced that the US court has declared the formulation patent of Seroquel XR to be valid. The patent covering the formulation of Seroquel XR expires in 2017 in both the EU and the US. The court ruled that the patent was infringed by Anchen Pharmaceuticals, Inc., Osmotica Pharmaceutical Corporation, Torrent Pharmaceuticals Limited, [...]
AstraZeneca plc (NYSE:AZN) announced that the US court has declared the formulation patent of Seroquel XR to be valid. The patent covering the formulation of Seroquel XR expires in 2017 in both the EU and the US. The court ruled that the patent was infringed by Anchen Pharmaceuticals, Inc., Osmotica Pharmaceutical Corporation, Torrent Pharmaceuticals Limited, Torrent Pharma Inc., Mylan Pharmaceuticals Inc. and Mylan Inc. (NYSE:MYL). |
©2013 MoneyShow.com, LLC. All Rights Reserved. For a complete trademark notice, please see the Terms of Service